Peters R W, Byington R, Arensberg D, Friedman L M, Romhilt D W, Barker A, Laubach C, Wilner G W, Goldstein S
J Chronic Dis. 1987;40(1):75-82. doi: 10.1016/0021-9681(87)90098-1.
In the Beta Blocker Heart Attack Trial, a double blind, randomized, controlled study, patients taking propranolol (180 or 240 mg/day) initiated 5-21 days post myocardial infarction had 26% fewer deaths than those taking placebo over a 25 month (mean) followup. Detailed analysis of the circumstances surrounding the BHAT deaths failed to reveal any striking difference between propranolol and placebo in the type of clinical event preceding death, the incidence and type of acute and prodromal signs and symptoms, the location of death, the activity preceding death or the percentage of deaths that were sudden or instantaneous, suggesting that propranolol may exert an "across the board" effect and improve survival by a combination of mechanisms. An unexpected finding was that the protective effect of propranolol appeared to occur during the hours of 10 p.m. to 7 a.m.
在β受体阻滞剂心肌梗死试验（一项双盲、随机、对照研究）中，心肌梗死后5 - 21天开始服用普萘洛尔（180或240毫克/天）的患者，在25个月（平均）的随访期内，死亡人数比服用安慰剂的患者少26%。对围绕β受体阻滞剂心肌梗死试验死亡情况的详细分析未能揭示普萘洛尔组和安慰剂组在死亡前临床事件类型、急性和前驱体征及症状的发生率和类型、死亡地点、死亡前的活动或猝死或即时死亡的百分比方面存在任何显著差异，这表明普萘洛尔可能产生“全面”效应，并通过多种机制的组合来提高生存率。一个意外的发现是，普萘洛尔的保护作用似乎发生在晚上10点至早上7点之间。
